Cantor Fitzgerald Weighs in on GH Research FY2026 Earnings

GH Research PLC (NASDAQ:GHRS) – Analysts at Cantor Fitzgerald issued their FY2026 EPS estimates for GH Research in a research note issued to investors on Monday, June 9th. Cantor Fitzgerald analyst C. Duncan anticipates that the company will post earnings of ($1.72) per share for the year. Cantor Fitzgerald currently has a “Overweight” rating and a $25.00 target price on the stock. The consensus estimate for GH Research’s current full-year earnings is ($0.80) per share.

GH Research (NASDAQ:GHRS) last announced its quarterly earnings data on Thursday, May 8th. The company reported ($0.19) EPS for the quarter, topping analysts’ consensus estimates of ($0.61) by $0.42.

Several other brokerages have also weighed in on GHRS. Royal Bank of Canada started coverage on shares of GH Research in a research note on Friday, March 7th. They set an “outperform” rating and a $31.00 target price for the company. Wall Street Zen downgraded shares of GH Research from a “hold” rating to a “sell” rating in a research report on Thursday, May 22nd. Guggenheim decreased their target price on GH Research from $32.00 to $29.00 and set a “buy” rating for the company in a research note on Friday, May 9th. HC Wainwright reiterated a “buy” rating and set a $40.00 target price on shares of GH Research in a research report on Friday, May 9th. Finally, Stifel Nicolaus upped their price target on shares of GH Research from $18.00 to $32.00 and gave the company a “buy” rating in a research report on Thursday, February 27th. One investment analyst has rated the stock with a sell rating and seven have issued a buy rating to the stock. According to MarketBeat, GH Research has a consensus rating of “Moderate Buy” and an average price target of $32.00.

GH Research Price Performance

GH Research stock opened at $12.84 on Tuesday. The stock has a market cap of $668.04 million, a price-to-earnings ratio of -16.25 and a beta of 0.97. GH Research has a 1-year low of $6.00 and a 1-year high of $20.50. The firm has a 50 day simple moving average of $10.51 and a 200-day simple moving average of $10.30.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of GHRS. BNP Paribas Financial Markets purchased a new position in GH Research in the fourth quarter valued at about $44,000. Two Sigma Investments LP acquired a new stake in shares of GH Research during the 4th quarter worth about $117,000. Palumbo Wealth Management LLC purchased a new stake in GH Research in the 1st quarter worth approximately $142,000. Millennium Management LLC purchased a new stake in shares of GH Research in the fourth quarter valued at $145,000. Finally, XTX Topco Ltd acquired a new position in shares of GH Research during the 1st quarter valued at about $169,000. Institutional investors and hedge funds own 56.90% of the company’s stock.

GH Research Company Profile

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).